|
Background: Relapse of CML on imatinib is most often
associated with point mutations in the BCR-ABL kinase domain. BMS-354825 is a
novel ABL kinase inhibitor with = 300-fold greater potency than imatinib and
preclinical activity against 14 of 15 imatinib resistant BCR-ABL mutants tested.
Unlike imatinib, BMS-354825 binds the ABL kinase domain in both active and
inactive conformations, and is thus predicted to have significant activity in
most imatinib-resistant CML and Ph+ ALL cases.
[BMS354825] A group for the BMS354825 clinical trial A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com |
[CML] A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com
